Literature DB >> 28417157

Impact of cachexia on outcomes in aggressive lymphomas.

Reem Karmali1, Taha Alrifai2, Ibtihaj A M Fughhi2, Ronald Ng3, Vineela Chukkapalli4, Palmi Shah5, Sanjib Basu2, Sunita Nathan4, Kelly Szymanski-Grant4, Leo I Gordon6,7, Parameswaran Venugopal4, Frank J Penedo7,8, Jeffrey A Borgia9.   

Abstract

Cancer cachexia is defined as a state of involuntary weight loss, attributed to altered body composition with muscle mass loss and/or loss of adiposity. Identifying the association between cancer cachexia and outcomes may pave the way for novel agents that target the cancer cachexia process. Clinical parameters for measurement of cancer cachexia are needed. We conducted a single-institution retrospective analysis that included 86 NHL patients with the aim of identifying an association between cancer cachexia and outcomes in aggressive lymphomas using the cachexia index (CXI) suggested by Jafri et al. (Clin Med Insights Oncol 9:87-93, 15). Impact of cachexia factors on progression-free survival (PFS) and overall survival (OS) were assessed using log-rank test and Cox proportional hazards regression. Patients were dichotomized around the median CXI into "non-cachectic" (CXI ≥49.8, n = 41) and "cachectic" (CXI <49.8, n = 40) groups. Cachectic patients had significantly worse PFS (HR 2.18, p = 0.044) and OS (HR = 4.05, p = 0.004) than non-cachectic patients. Cachexia as defined by the CXI is prognostic in aggressive lymphomas and implies that novel therapeutic strategies directed at reversing cachexia may improve survival in this population.

Entities:  

Keywords:  Cachexia; DLBCL; Non-Hodgkin lymphomas; Outcomes; Pathophysiology; Prognostic factors

Mesh:

Year:  2017        PMID: 28417157     DOI: 10.1007/s00277-017-2958-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  11 in total

1.  Limitations of the L3 skeletal muscle index and the Asian Working Group for Sarcopenia 2019 consensus diagnostic criteria for sarcopenia evaluation in a case of diffuse large B-cell lymphoma.

Authors:  Takuya Matsunaga; Tomoko Deto; Tomoe Yamada; Takashi Yamamoto; Kimika Yamakawa; Yuta Kamiyama; Masako Morimoto; Hitoshi Seki; Fumihiko Haraguchi; Ikuko Hisatomi; Katsuya Nakanishi; Masahiro Takahashi
Journal:  Clin Case Rep       Date:  2022-06-19

2.  Low skeletal muscle mass and post-operative complications after surgery for liver malignancies: a meta-analysis.

Authors:  Maximilian Thormann; Jazan Omari; Maciej Pech; Robert Damm; Roland Croner; Aristotelis Perrakis; Alexandra Strobel; Andreas Wienke; Alexey Surov
Journal:  Langenbecks Arch Surg       Date:  2022-05-18       Impact factor: 2.895

3.  Clinical significance of the cachexia index in patients with small cell lung cancer.

Authors:  Se-Il Go; Mi Jung Park; Gyeong-Won Lee
Journal:  BMC Cancer       Date:  2021-05-17       Impact factor: 4.430

4.  Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review.

Authors:  Markus S Anker; Richard Holcomb; Maurizio Muscaritoli; Stephan von Haehling; Wilhelm Haverkamp; Aminah Jatoi; John E Morley; Florian Strasser; Ulf Landmesser; Andrew J S Coats; Stefan D Anker
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-02       Impact factor: 12.910

5.  Preoperative Cachexia predicts poor outcomes in young rather than elderly gastric cancer patients: a prospective study.

Authors:  Xiaodong Chen; Yunpeng Zeng; Yunshi Huang; Jingxuan Xu; Weiyang Meng; Xiang Wang; Ce Zhu; Guanbao Zhu; Chenchen Mao; Xian Shen
Journal:  Cancer Manag Res       Date:  2019-09-02       Impact factor: 3.989

6.  Prognostic Role of Pre-Treatment Metabolic Parameters and Sarcopenia Derived by 2-[18F]-FDG PET/CT in Elderly Mantle Cell Lymphoma.

Authors:  Domenico Albano; Nadia Pasinetti; Francesco Dondi; Raffaele Giubbini; Alessandra Tucci; Francesco Bertagna
Journal:  J Clin Med       Date:  2022-02-23       Impact factor: 4.241

7.  Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B-cell lymphoma.

Authors:  Se-Il Go; Mi Jung Park; Sungwoo Park; Myoung Hee Kang; Hoon-Gu Kim; Jung Hun Kang; Jung Hoon Kim; Gyeong-Won Lee
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-10-21       Impact factor: 12.910

8.  Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy.

Authors:  Myung Ji Goh; Wonseok Kang; Woo Kyoung Jeong; Dong Hyun Sinn; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik
Journal:  Sci Rep       Date:  2022-05-10       Impact factor: 4.996

9.  Sarcopenia does not predict outcome in patients with CNS lymphoma undergoing systemic therapy.

Authors:  Vincenzo Ferraro; Maximilian Thormann; Mattes Hinnerichs; Maciej Pech; Denise Wolleschak; Dimitrios Mougiakakos; Andreas Wienke; Alexandra Strobel; Vanja Zeremski; Alexey Surov; Jazan Omari
Journal:  Oncol Lett       Date:  2022-08-22       Impact factor: 3.111

10.  Prognostic value of cachexia index in patients with colorectal cancer: A retrospective study.

Authors:  Qianyi Wan; Qian Yuan; Rui Zhao; Xiaoding Shen; Yi Chen; Tao Li; Yinghan Song
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.